Author(s): Novotna A, Mares J, Ratcliffe S, Novakova I, Zapletalova O, et al
Background: Spasticity is a disabling complication of multiple sclerosis, affecting many patients with the condition. We report the first Phase 3 placebo-controlled study of an oral antispasticity agent to use an enriched study design.
Methods: A 19-week follow-up, multicentre, double-blind, randomized, placebo-controlled, parallel-group study in subjects with multiple sclerosis spasticity not fully relieved with current antispasticity therapy. Subjects were treated with nabiximols, as add-on therapy, in a single-blind manner for 4weeks, after which those achieving an improvement in spasticity of ≥20% progressed to a 12-week randomized, placebo-controlled phase.
Results: Of the 572 subjects enrolled, 272 achieved a ≥20% improvement after 4weeks of single-blind treatment, and 241 were randomized. The primary end-point was the difference between treatments in the mean spasticity Numeric Rating Scale (NRS) in the randomized, controlled phase of the study. Intention-to-treat (ITT) analysis showed a highly significant difference in favour of nabiximols (P=0.0002). Secondary end-points of responder analysis, Spasm Frequency Score, Sleep Disturbance NRS Patient, Carer and Clinician Global Impression of Change were all significant in favour of nabiximols.
Conclusions: The enriched study design provides a method of determining the efficacy and safety of nabiximols in a way that more closely reflects proposed clinical practice, by limiting exposure to those patients who are likely to benefit from it. Hence, the difference between active and placebo should be a reflection of efficacy and safety in the population intended for treatment.
Referred From: https://pubmed.ncbi.nlm.nih.gov/21362108/
Author(s): Rizzo MA, Hadjimichael OC, Preiningerova J, Vollmer TL
Author(s): Beard S, Hunn A, Wight J
Author(s): Shakespeare DT, Boggild M, Young C
Author(s): Russo EB
Author(s): Schoedel KA, Chen N, Hilliard A, White L, Stott C, et al.
Author(s): Wade DT, Makela P, Robson P, House H, Bateman C
Author(s): Collin C, Davies P, Mutiboko IK, Ratcliffe S; Sativex Spasticity in MS Study Group
Author(s): Wade DT, Collin C, Stott C, Duncombe P
Author(s): Serpell MG, Notcutt W, Collin C
Author(s): Mechoulam R, Parker LA
Author(s): Bovasso GB
Author(s): Degenhardt L, Hall W, Lynskey M
Author(s): Lynskey MT, Glowinski AL, Todorov AA, Bucholz KK, Madden PA, et al.
Author(s): Dougherty DM, Mathias CW, Dawes MA, Furr RM, Charles N, et al.
Author(s): Achiron A, Chapman J, Magalashvili D, Dolev M, Lavie M, et al.
Author(s): Stott CG, White L, Wright S, Wilbraham D, Guy GW
Author(s): Fischer JS, Rudick RA, Cutter GR, Reingold SC
Author(s): Bohannon RW, Smith MB
Author(s): Endler NS, Rutherford A, Denisoff E
Author(s): Rog DJ, Nurmikko TJ, Friede T, Young CA
Author(s): Collin C, Ehler E, Waberzinek G, Alsindi Z, Davies P et al.
Author(s): Feinstein A
Author(s): Notcutt WG
Author(s): Pandyan AD, Johnson GR, Price CI, Curless RH, Barnes MP et al.
Author(s): Nurmikko TJ, Serpell MG, Hoggart B, Toomey PJ, Morlion BJ et al.